ATE289605T1 - Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung - Google Patents

Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung

Info

Publication number
ATE289605T1
ATE289605T1 AT00993610T AT00993610T ATE289605T1 AT E289605 T1 ATE289605 T1 AT E289605T1 AT 00993610 T AT00993610 T AT 00993610T AT 00993610 T AT00993610 T AT 00993610T AT E289605 T1 ATE289605 T1 AT E289605T1
Authority
AT
Austria
Prior art keywords
field
blood clotting
substituted oxazolidinones
oxazolidinones
substituted
Prior art date
Application number
AT00993610T
Other languages
German (de)
English (en)
Inventor
Alexander Straub
Thomas Lampe
Jens Pohlmann
Susanne Roehrig
Elisabeth Perzborn
Karl-Heinz Schlemmer
Joseph Pernerstorfer
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7934434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE289605(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of ATE289605T1 publication Critical patent/ATE289605T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT00993610T 1999-12-24 2000-12-11 Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung ATE289605T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962924A DE19962924A1 (de) 1999-12-24 1999-12-24 Substituierte Oxazolidinone und ihre Verwendung
PCT/EP2000/012492 WO2001047919A1 (de) 1999-12-24 2000-12-11 Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung

Publications (1)

Publication Number Publication Date
ATE289605T1 true ATE289605T1 (de) 2005-03-15

Family

ID=7934434

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00993610T ATE289605T1 (de) 1999-12-24 2000-12-11 Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung

Country Status (48)

Country Link
US (8) US7157456B2 (OSRAM)
EP (2) EP1526132B1 (OSRAM)
JP (2) JP4143297B2 (OSRAM)
KR (3) KR20070094672A (OSRAM)
CN (3) CN100549008C (OSRAM)
AR (1) AR032436A1 (OSRAM)
AT (1) ATE289605T1 (OSRAM)
AU (2) AU775126C (OSRAM)
BE (1) BE2008C046I2 (OSRAM)
BG (1) BG65683B1 (OSRAM)
BR (1) BR0017050B1 (OSRAM)
CA (1) CA2396561C (OSRAM)
CO (1) CO5251440A1 (OSRAM)
CU (2) CU23208A3 (OSRAM)
CY (2) CY2008019I1 (OSRAM)
CZ (1) CZ301432B6 (OSRAM)
DE (3) DE19962924A1 (OSRAM)
DK (2) DK1261606T3 (OSRAM)
DO (2) DOP2000000114A (OSRAM)
EE (1) EE05169B1 (OSRAM)
ES (2) ES2457021T3 (OSRAM)
FR (1) FR08C0051I2 (OSRAM)
GT (1) GT200000216A (OSRAM)
HN (1) HN2000000267A (OSRAM)
HR (2) HRP20020617B1 (OSRAM)
HU (1) HU226522B1 (OSRAM)
IL (2) IL149896A0 (OSRAM)
LT (1) LTC1261606I2 (OSRAM)
LU (1) LU91497I2 (OSRAM)
MA (1) MA25646A1 (OSRAM)
MX (1) MXPA02006241A (OSRAM)
MY (1) MY140488A (OSRAM)
NL (1) NL300370I2 (OSRAM)
NO (4) NO323699B1 (OSRAM)
NZ (2) NZ519730A (OSRAM)
PE (1) PE20010963A1 (OSRAM)
PL (2) PL201121B1 (OSRAM)
PT (2) PT1261606E (OSRAM)
SG (1) SG130939A1 (OSRAM)
SI (2) SI1261606T1 (OSRAM)
SK (1) SK287272B6 (OSRAM)
SV (1) SV2002000245A (OSRAM)
TR (2) TR200201636T2 (OSRAM)
TW (2) TWI226330B (OSRAM)
UA (1) UA73339C2 (OSRAM)
UY (1) UY34152A (OSRAM)
WO (1) WO2001047919A1 (OSRAM)
ZA (1) ZA200204188B (OSRAM)

Families Citing this family (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US7390825B1 (en) 2001-10-18 2008-06-24 Board Of Trustees Of Michigan State University Process for the preparation of oxazolidinones and method of use thereof
DE10152460A1 (de) * 2001-10-24 2003-05-08 Bayer Ag Stents
JP2005512975A (ja) 2001-10-25 2005-05-12 アストラゼネカ アクチボラグ 抗菌薬として有用なイソキサゾリン誘導体
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US7012088B2 (en) 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
DE10336716A1 (de) * 2003-08-11 2005-03-10 Merck Patent Gmbh Verfahren zur Herstellung von N-Aryl-morpholinonen
DE10342570A1 (de) * 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
US7371743B2 (en) * 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1747217A1 (de) * 2004-05-13 2007-01-31 Boehringer Ingelheim International GmbH Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
JP2007537179A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換チオフェン−２−カルボン酸アミド、その製法及び薬物としての使用
KR101195801B1 (ko) * 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE602004020812D1 (de) * 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
TW200612923A (en) * 2004-07-29 2006-05-01 Ferrer Int Oxazolidinone compounds and compositions and methods related thereto
DE102004047840A1 (de) 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE102004050283A1 (de) * 2004-10-15 2006-04-27 Lanxess Deutschland Gmbh 4-Aminophenyl-morpholinon-Derivate und deren Herstellung
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
NZ555289A (en) 2004-10-22 2010-10-29 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1843734A4 (en) 2005-02-03 2008-09-10 Signum Biosciences Inc COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION
DE102005018690A1 (de) * 2005-04-22 2006-10-26 Bayer Healthcare Ag Imino-oxazolidine und ihre Verwendung
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006021306D1 (OSRAM) 2005-06-27 2011-05-26 Bristol Myers Squibb Co
PE20070171A1 (es) * 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
WO2007007588A1 (ja) * 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
US20070032473A1 (en) * 2005-07-19 2007-02-08 Kai Gerlach Substituted amides and their use as medicaments
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047564A1 (de) * 2005-10-04 2007-05-31 Bayer Healthcare Ag Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
AU2006299126B2 (en) * 2005-10-04 2012-06-28 Bayer Intellectual Property Gmbh Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005048824A1 (de) * 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
WO2007048088A2 (en) 2005-10-18 2007-04-26 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
US7962847B2 (en) * 2005-10-20 2011-06-14 International Business Machines Corporation Method for providing dynamic process step annotations
DE102005052174A1 (de) * 2005-11-02 2007-06-06 Bayer Healthcare Ag Phenylen-bis-oxazolidin-Derivate und ihre Verwendung
JP2007154330A (ja) * 2005-12-01 2007-06-21 Nippon Paper Industries Co Ltd 印刷用塗工紙
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
JP5161070B2 (ja) 2006-03-31 2013-03-13 財団法人乙卯研究所 ヘテロ環を有する新規化合物
EP2015748B1 (en) 2006-04-20 2012-07-04 Janssen Pharmaceutica NV A C-Kit kinase inhibitor for use in the treatment of gastrointestinal stromal tumor or mastocytosis
CN101472914B (zh) 2006-04-20 2015-05-20 詹森药业有限公司 C-fms激酶抑制剂
US8674100B2 (en) 2006-04-20 2014-03-18 Janssen Pharmaceutica, N.V. Inhibitors of C-FMS kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
SI2021335T1 (sl) * 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocikliäśne spojine kot zaviralci c-fms kinaze
NZ572418A (en) 2006-05-05 2011-08-26 Millennium Pharm Inc Factor xa inhibitors
DE102006025319A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Aktiengesellschaft Substituierte Heterozyklen und ihre Verwendung
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006034916A1 (de) * 2006-07-28 2008-01-31 Bayer Healthcare Ag Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
JP5342450B2 (ja) 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
JPWO2008120655A1 (ja) * 2007-03-30 2010-07-15 株式会社医薬分子設計研究所 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体
DE102007018662A1 (de) 2007-04-20 2008-10-23 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
EP2148871A1 (en) 2007-04-23 2010-02-03 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
KR101009594B1 (ko) 2007-05-09 2011-01-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물
WO2008140220A1 (en) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028318A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
DE102007028320A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
WO2009018807A1 (de) * 2007-08-06 2009-02-12 Schebo Biotech Ag Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
DE102007037373A1 (de) 2007-08-06 2009-02-19 Schebo Biotech Ag Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
US20090076264A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched rivaroxaban
CN101883768A (zh) * 2007-10-02 2010-11-10 财团法人乙卯研究所 具有7元杂环的噁唑烷酮衍生物
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2220079A2 (en) * 2007-11-15 2010-08-25 Boehringer Ingelheim International GmbH Substituted amides, manufacturing and use thereof as medicaments
EP2229173A1 (en) * 2007-12-11 2010-09-22 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment and/or prophylaxis of heart failure
JP5504171B2 (ja) 2007-12-26 2014-05-28 サノフイ Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
WO2009132051A1 (en) 2008-04-21 2009-10-29 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
DE102008028071A1 (de) 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
EP2138178A1 (en) * 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
KR100898361B1 (ko) * 2008-07-03 2009-05-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
EP2140866A1 (en) * 2008-07-04 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
US20110300214A1 (en) 2008-07-08 2011-12-08 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid
KR101023174B1 (ko) * 2008-09-24 2011-03-18 주식회사 레고켐 바이오사이언스 사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
UY32407A (es) * 2009-01-30 2010-07-30 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
ES2606127T5 (es) 2009-06-18 2020-02-17 Krka Tovarna Zdravil D D Novo Mesto Composición farmacéutica sólida que comprende rivaroxabán
EP2266541A1 (en) 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
KR101037051B1 (ko) 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 (ｓ)-5-클로로-ｎ-((3-(4-(5,6-다이하이드로-4ｈ-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법
KR101037052B1 (ko) 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체
PL2459555T3 (pl) * 2009-07-31 2022-03-28 Krka, D.D., Novo Mesto Sposoby krystalizacji rywaroksabanu
EP2485715A1 (en) 2009-10-06 2012-08-15 Ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
WO2011061760A1 (en) * 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
CN102762550B (zh) 2009-12-17 2015-04-01 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
EP2521723A1 (en) 2010-01-04 2012-11-14 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
EP2354128A1 (en) * 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
EP3786165A1 (en) 2010-02-11 2021-03-03 Bristol-Myers Squibb Company Synthetic intermediates for producing macrocycles as factor xia inhibitors
EA015918B1 (ru) 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
DE102010018299A1 (de) 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2388260A1 (de) 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN102311400A (zh) * 2010-06-29 2012-01-11 翔真生物科技股份有限公司 制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en) 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (cs) 2010-09-30 2012-04-11 Farmak, A. S. Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
WO2012051692A1 (en) 2010-10-18 2012-04-26 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
DE102010063127A1 (de) 2010-12-15 2012-06-21 Bayer Schering Pharma Aktiengesellschaft Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
JP2014506448A (ja) 2011-01-19 2014-03-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 凝固因子の阻害剤に対する結合タンパク質
CN102199150A (zh) * 2011-04-01 2011-09-28 中国药科大学 光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途
WO2012140061A1 (en) 2011-04-11 2012-10-18 Sandoz Ag Method for the preparation of substituted oxazolidinones
US9556163B2 (en) * 2011-05-06 2017-01-31 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of a rivaroxaban and intermediates formed in said process
WO2012156983A1 (en) * 2011-05-16 2012-11-22 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
ES2395304B1 (es) * 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
CN102796091A (zh) * 2011-05-24 2012-11-28 北大方正集团有限公司 取代的噁唑烷酮化合物及其制备方法和应用
CN102796092B (zh) * 2011-05-24 2015-04-08 北大方正集团有限公司 噁唑烷酮衍生物及其制备方法和应用
CN102320988B (zh) * 2011-06-03 2014-04-09 中国科学院上海有机化学研究所 4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途
CN102827154B (zh) 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
WO2013098833A2 (en) 2011-09-08 2013-07-04 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
EP2573084A1 (en) 2011-09-22 2013-03-27 Enantia, S.L. Novel crystalline forms of rivaroxaban and processes for their preparation
WO2013046211A1 (en) * 2011-09-27 2013-04-04 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof
WO2013053739A1 (en) 2011-10-10 2013-04-18 Laboratorios Lesvi, S. L. Process for preparing factor xa inhibitors
HU230734B1 (hu) 2011-10-10 2017-12-28 EGIS Gyógyszergyár Nyrt Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok
JP6162704B2 (ja) * 2011-10-11 2017-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ オキサゾリジノン誘導体のシラアナログ及びその合成
CN103987697B (zh) 2011-10-14 2017-04-26 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
US9079929B2 (en) 2011-10-14 2015-07-14 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
DK2766346T3 (en) 2011-10-14 2017-07-03 Bristol Myers Squibb Co SUBSTITUTED TETRAHYDROISOQUINOL COMPOUNDS AS FACTOR XIA INHIBITORS
CN102408420B (zh) * 2011-10-19 2014-10-22 汕头经济特区鮀滨制药厂 一种利伐沙班及其中间体的制备方法以及中间体化合物
EP2812329A2 (en) 2012-02-06 2014-12-17 Megafine Pharma (P) Ltd. A process for preparation of rivaroxaban and intermediates thereof
CZ2012111A3 (cs) 2012-02-16 2013-08-28 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na vyuzití (S)-epichlorhydrinu
CZ2012114A3 (cs) 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
CN103288814B (zh) 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
WO2013151719A2 (en) * 2012-04-05 2013-10-10 Scifluor Life Sciences, Llc Fluorinated oxazolidinone derivatives
JP2015514114A (ja) 2012-04-06 2015-05-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ リバーロキサバンを調製するためのプロセス
US20150299160A1 (en) 2012-04-16 2015-10-22 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban and intermediates thereof
BR112014027248B1 (pt) * 2012-05-02 2021-01-26 Symed Labs Limited processo em um único recipiente para preparar rivaroxaban
SG11201407518SA (en) * 2012-05-24 2014-12-30 Ranbaxy Lab Ltd Process for the preparation of rivaroxaban
CN102746287B (zh) * 2012-06-21 2014-05-28 成都苑东药业有限公司 一种恶唑烷酮化合物及其制备方法
UY34856A (es) 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
CN102757424B (zh) * 2012-07-09 2014-10-15 云南大学 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
CN102746288B (zh) * 2012-07-24 2015-04-08 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法
US9376444B2 (en) 2012-08-03 2016-06-28 Bristol-Myers Squibb Company Dihydropyridone P1 as factor XIa inhibitors
UY34960A (es) 2012-08-03 2014-01-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Dihidropiridona p1 como inhibidores del factor xia
WO2014025675A1 (en) 2012-08-07 2014-02-13 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
US20150218145A1 (en) 2012-09-26 2015-08-06 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban
CN103864773B (zh) * 2012-12-13 2017-03-15 北京藏卫信康医药研发有限公司 利伐沙班及其中间体的制备方法
ES2647607T3 (es) * 2012-12-21 2017-12-22 Farma Grs, D.O.O. Procedimiento para la preparación de rivaroxabán
BR112015011033A2 (pt) 2012-12-26 2017-07-11 Wanbury Ltd derivado aldeído de oxazolidinonas substituídas
EP2895176B1 (en) 2012-12-26 2016-10-19 Wanbury Limited Rivaroxaban intermediate and preparation thereof
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
IN2013MU01113A (OSRAM) 2013-03-25 2015-06-19 Glenmark Generics Ltd
CN104098556B (zh) * 2013-04-09 2019-01-08 浙江九洲药物科技有限公司 一种利伐沙班的合成工艺
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
CN104163819A (zh) * 2013-05-17 2014-11-26 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
UY35592A (es) 2013-06-03 2014-12-31 Bayer Pharma AG Benzoxazoles sustituidos
CN105408331A (zh) * 2013-06-03 2016-03-16 拜耳制药股份公司 作为用于治疗血栓栓塞病症的凝血酶抑制剂的三唑并吡啶
CA2913958A1 (en) 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted benzoxazoles
WO2015011617A1 (en) 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban
WO2015026761A1 (en) * 2013-08-19 2015-02-26 Amneal Pharmaceuticals Llc A process for the preparation of rivaroxaban
IN2014MU00072A (OSRAM) 2014-01-08 2015-08-21 Wockhardt Ltd
IN2014CH00290A (OSRAM) 2014-01-23 2015-08-14 Symed Labs Ltd
NO2760821T3 (OSRAM) 2014-01-31 2018-03-10
HRP20181339T1 (hr) 2014-01-31 2018-12-28 Bristol-Myers Squibb Company Makrociklusi sa heterocikličkim p2' grupama kao inhibitori faktora xia
WO2015124995A1 (en) 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104974149B (zh) * 2014-04-14 2018-05-01 北大方正集团有限公司 一种利伐沙班的制备方法
CN105085371B (zh) * 2014-04-22 2017-06-16 北大方正集团有限公司 (s)‑{1‑(氯甲酸酯基)‑2‑[2‑(1,3‑二氧异吲哚)基]乙基}卤化盐及其制备方法
KR101499867B1 (ko) * 2014-04-22 2015-03-06 에스케이케미칼주식회사 활성 성분 (i) 함유 조성물 및 이의 제조 방법
CN105085370B (zh) * 2014-04-22 2017-04-12 北大方正集团有限公司 (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
WO2015169957A1 (en) 2014-05-09 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists
CN104031036A (zh) * 2014-05-16 2014-09-10 南通常佑药业科技有限公司 一种利伐沙班的制备方法
KR102412045B1 (ko) 2014-05-22 2022-06-22 놀스 차이나 파마수티칼 컴퍼니., 엘티디. 혈액응고인자 Xa 억제제로서의 히드라지드 화합물
CN103980221B (zh) * 2014-05-26 2016-03-23 山东康美乐医药科技有限公司 4-（硝基苯基）-3-吗啉酮的制备方法及利用其制备利伐沙班的方法
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2015198259A1 (en) 2014-06-26 2015-12-30 Erregierre S.P.A. Process for the synthesis of rivaroxaban and intermediate for the production thereof
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
HUE040133T2 (hu) 2014-07-15 2019-02-28 Gruenenthal Gmbh Szubsztituált azaspiro(4.5)dekán származékok
CN104086539A (zh) * 2014-07-17 2014-10-08 天津炜捷制药有限公司 一种利伐沙班的制备方法
WO2016030669A1 (en) 2014-08-25 2016-03-03 Cipla Limited Process for the preparation of rivaroxaban
NO2721243T3 (OSRAM) 2014-10-01 2018-10-20
CN104356124A (zh) * 2014-10-30 2015-02-18 广东东阳光药业有限公司 噁唑烷酮类化合物及其组合物和用途
CN104402876A (zh) * 2014-11-25 2015-03-11 沈阳药科大学 噁唑烷酮类化合物及其应用
CN104478869B (zh) * 2014-12-05 2017-04-12 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447729A (zh) * 2014-12-05 2015-03-25 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447728B (zh) * 2014-12-05 2017-01-04 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104478866B (zh) * 2014-12-05 2017-07-07 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104496978A (zh) * 2014-12-09 2015-04-08 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
CN104497008B (zh) * 2014-12-09 2016-11-16 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
CN104530029B (zh) * 2014-12-09 2017-04-12 广东东阳光药业有限公司 作为Xa因子抑制剂的杂环化合物及其使用方法和用途
CN104530030A (zh) * 2014-12-10 2015-04-22 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104530031A (zh) * 2014-12-10 2015-04-22 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104530080B (zh) * 2014-12-10 2017-01-11 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN105777734A (zh) * 2014-12-22 2016-07-20 常州方楠医药技术有限公司 一种利伐沙班中间体的合成方法
CN104557900A (zh) * 2014-12-23 2015-04-29 中国药科大学 噁唑烷酮类化合物及其制备方法与医药用途
CN105820161A (zh) * 2015-01-08 2016-08-03 常州方楠医药技术有限公司 一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法
TR201501970A2 (en) 2015-02-19 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dronedarone.
PE20171349A1 (es) 2015-03-20 2017-09-13 Hoffmann La Roche Inhibidores de bace1
WO2016150937A1 (en) 2015-03-25 2016-09-29 Lonza Ltd Method for preparation of thiophenecarbonyl chlorides
CN104926807B (zh) * 2015-06-04 2017-10-31 沈阳药科大学 一种利伐沙班相关物质“二胺”及其合成方法
CN108026083B (zh) 2015-06-19 2021-08-27 百时美施贵宝公司 作为因子xia抑制剂的二酰胺大环
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
US10336730B2 (en) 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors
JP6410989B2 (ja) 2015-11-04 2018-10-24 ロンザ・リミテッド 塩化オキサリルを用いたチオフェン−２−カルボニルクロリド類の調製方法
EP3978072A1 (en) 2016-02-23 2022-04-06 Morgandane Scientific, LLC Method of treating patients coadministered a factor xa inhibitor and verapamil
US10752641B2 (en) 2016-03-02 2020-08-25 Bristol-Myers Squibb Company Diamide macrocycles having factor XIa inhibiting activity
WO2018001914A1 (en) 2016-06-28 2018-01-04 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical capsule composition of rivaroxaban
CN106588905A (zh) * 2016-12-13 2017-04-26 重庆英斯凯化工有限公司 一种利伐沙班中间体的制备方法
WO2018127762A1 (en) * 2017-01-04 2018-07-12 Unichem Laboratories Ltd An improved process for the preparation of rivaroxaban involving novel intermediate
CN107586291B (zh) * 2017-11-03 2019-08-20 梯尔希（南京）药物研发有限公司 一种利伐沙班代谢物5的合成方法
CN107857739A (zh) * 2017-11-14 2018-03-30 安徽华胜医药科技有限公司 一种氘代利伐沙班关键中间体及其制备方法
CN107857761A (zh) * 2017-11-14 2018-03-30 安徽华胜医药科技有限公司 一种氘代利伐沙班及其制备方法
CN108164519A (zh) * 2017-12-28 2018-06-15 江苏悦兴医药技术有限公司 利伐沙班工艺杂质的合成方法
EP3505160A1 (en) 2017-12-31 2019-07-03 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof
HU231119B1 (hu) 2018-01-12 2020-11-30 Richter Gedeon Nyrt. Eljárás 4-(4-aminofenil)morfolin-3-on előállítására
US10828310B2 (en) 2018-02-02 2020-11-10 Bayer Pharma Aktiengesellschaft Reducing the risk of cardiovascular events
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
CN108546265A (zh) * 2018-06-22 2018-09-18 苏州中联化学制药有限公司 一种利伐沙班中间体的合成方法
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
EP3796915A4 (en) 2018-11-16 2022-01-26 Santa Farma Ilaç Sanayi A.S. ORAL FORMULATIONS CONTAINING RIVAROXABAN
CN110054621A (zh) * 2019-03-12 2019-07-26 浙江天宇药业股份有限公司 一种利伐沙班中间体的制备方法
CN110615756A (zh) * 2019-06-28 2019-12-27 南京红杉生物科技有限公司 1-(4-硝基苯基)哌啶-2-酮及其合成方法和应用
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives
CN111253383A (zh) * 2020-03-27 2020-06-09 南京国星生物技术研究院有限公司 一种利伐沙班的合成方法
CN112159402B (zh) * 2020-10-28 2022-04-05 南京法恩化学有限公司 一种利伐沙班的制备方法
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
CN115260117B (zh) * 2022-08-09 2024-05-28 江苏法安德医药科技有限公司 一种4-(4-氨基苯基)吗啡啉-3-酮的合成方法
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1035546B (de) 1955-02-16 1958-07-31 Max Ruf Torbegrenzung fuer Ballspiele
US2811555A (en) * 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) * 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) * 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ES533097A0 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
CA1317594C (en) 1987-10-21 1993-05-11 Chung-Ho Park Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
DE69216251T2 (de) * 1991-11-01 1997-05-15 Pharmacia & Upjohn Co., Kalamazoo, Mich. Substituierte aryl- und heteroaryl-phenyloxazolidinone
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) * 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
ATE181735T1 (de) 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
RU2154645C2 (ru) * 1995-02-03 2000-08-20 Фармация Энд Апджон Компани Фенилоксазолидиноны, замещенные в кольце гетероароматическими кольцами, в качестве антимикробных агентов
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0856002B1 (en) 1995-09-01 2001-10-24 PHARMACIA & UPJOHN COMPANY Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) * 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DE69731840T2 (de) 1996-07-15 2005-08-04 Sankyo Co., Ltd. Pharmazeutische Zusammensetzungen enthaltend CS-866 und Insulinresistenz verbessernde Mittel und deren Verwendung zur Behandlung von Arteriosklerose und Xanthom
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
ATE293609T1 (de) 1997-05-30 2005-05-15 Upjohn Co Antibakteriell wirksam oxazolidinone mit einer thiocarbonylfunktionalität
US5977373A (en) 1997-07-11 1999-11-02 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
ATE250054T1 (de) 1997-11-12 2003-10-15 Upjohn Co Oxazolidinone derivate und pharmazeutische zusammensetzungen
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
DE19802239A1 (de) 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
NZ505902A (en) 1998-01-23 2003-08-29 Upjohn Co Oxazolidinone compounds useful as antimicrobial agents and combinatorial libraries
WO1999037304A1 (en) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
ATE222115T1 (de) * 1998-05-18 2002-08-15 Upjohn Co Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
PL356478A1 (en) 1999-12-21 2004-06-28 Pharmacia & Upjohn Company Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CN1413218A (zh) 1999-12-28 2003-04-23 味之素株式会社 天冬甜素衍生物的结晶
KR100415318B1 (ko) 2000-09-23 2004-01-16 탁승호 레이저를 이용한 수평 및 수직선 지시계
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
CN103143006B (zh) 2005-02-14 2016-08-03 埃皮托皮克斯有限责任公司 来自金黄色葡萄球菌的多肽和使用方法
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
AU2006299126B2 (en) 2005-10-04 2012-06-28 Bayer Intellectual Property Gmbh Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
KR101378695B1 (ko) * 2007-04-18 2014-03-31 삼성전자주식회사 통신 시스템에서의 훈련 시퀀스 코드 생성 방법 및 장치

Also Published As

Publication number Publication date
LU91497I9 (OSRAM) 2019-01-02
SG130939A1 (en) 2007-04-26
US20150166568A1 (en) 2015-06-18
CN1262551C (zh) 2006-07-05
EP1526132A2 (de) 2005-04-27
HK1103235A1 (en) 2007-12-14
US20080090815A1 (en) 2008-04-17
US8129378B2 (en) 2012-03-06
CZ301432B6 (cs) 2010-03-03
KR20070044075A (ko) 2007-04-26
TW200422299A (en) 2004-11-01
AU775126C (en) 2005-09-01
PL200413B1 (pl) 2009-01-30
EE200200341A (et) 2003-10-15
NO323699B1 (no) 2007-06-25
NO2021009I1 (no) 2021-02-25
CN1900074B (zh) 2012-07-11
NZ537058A (en) 2006-04-28
SK9082002A3 (en) 2003-04-01
BR0017050A (pt) 2002-11-05
HN2000000267A (es) 2001-06-13
DE50009607D1 (de) 2005-03-31
HRP20020617A2 (en) 2004-12-31
US20060258724A1 (en) 2006-11-16
ES2457021T3 (es) 2014-04-24
DOP2008000001A (es) 2010-01-15
KR20020067569A (ko) 2002-08-22
JP2005068164A (ja) 2005-03-17
CY1115117T1 (el) 2016-12-14
US20130005701A1 (en) 2013-01-03
AU775126B2 (en) 2004-07-15
US20130316999A1 (en) 2013-11-28
BG65683B1 (bg) 2009-06-30
PE20010963A1 (es) 2001-11-10
CY2008019I2 (el) 2009-11-04
HRP20020617B1 (en) 2006-09-30
MY140488A (en) 2009-12-31
MXPA02006241A (es) 2003-01-28
NL300370I1 (nl) 2009-02-02
NO20070981L (no) 2002-08-14
JP2003519141A (ja) 2003-06-17
NO2009001I1 (no) 2009-02-02
HU226522B1 (en) 2009-03-30
CU23208A3 (es) 2007-06-20
UY34152A (es) 2013-02-28
HUP0203902A3 (en) 2003-07-28
ES2237497T3 (es) 2005-08-01
EP1526132A3 (de) 2005-08-31
LTPA2008018I1 (lt) 2021-04-12
WO2001047919A1 (de) 2001-07-05
WO2001047919A9 (de) 2002-12-19
DK1526132T3 (da) 2014-06-16
JP4143297B2 (ja) 2008-09-03
RU2002120456A (ru) 2004-01-10
EP1261606A1 (de) 2002-12-04
CN1900074A (zh) 2007-01-24
US8822458B2 (en) 2014-09-02
SK287272B6 (sk) 2010-05-07
HK1092140A1 (zh) 2007-02-02
CN1772751A (zh) 2006-05-17
US7157456B2 (en) 2007-01-02
DOP2000000114A (es) 2002-07-15
TWI226330B (en) 2005-01-11
NL300370I2 (nl) 2009-05-06
SV2002000245A (es) 2002-01-15
CO5251440A1 (es) 2003-02-28
CN100549008C (zh) 2009-10-14
PL201121B1 (pl) 2009-03-31
NO2009001I2 (OSRAM) 2010-05-11
NO20023043L (no) 2002-08-14
SI1261606T1 (OSRAM) 2005-08-31
ZA200204188B (en) 2003-05-27
IL205242A0 (en) 2011-07-31
US8530505B2 (en) 2013-09-10
AU2004218729A1 (en) 2004-11-04
GT200000216A (es) 2002-06-12
AU2841401A (en) 2001-07-09
RU2297415C2 (ru) 2007-04-20
CZ20022202A3 (cs) 2002-11-13
HRP20060251A2 (en) 2006-12-31
DE19962924A1 (de) 2001-07-05
CU23423B7 (es) 2009-09-08
TR200201636T2 (tr) 2002-10-21
PT1526132E (pt) 2014-04-15
SI1526132T1 (sl) 2014-07-31
NZ519730A (en) 2005-02-25
KR20070094672A (ko) 2007-09-20
BE2008C046I2 (OSRAM) 2019-12-16
CY2008019I1 (el) 2009-11-04
EP1261606B1 (de) 2005-02-23
US20080200674A1 (en) 2008-08-21
DE122009000014I1 (de) 2009-11-05
FR08C0051I2 (fr) 2009-12-18
LU91497I2 (fr) 2009-01-19
NO20023043D0 (no) 2002-06-21
PT1261606E (pt) 2005-07-29
IL149896A0 (en) 2002-11-10
IL205242A (en) 2011-12-29
US7576111B2 (en) 2009-08-18
US20100137274A1 (en) 2010-06-03
EE05169B1 (et) 2009-06-15
BR0017050B1 (pt) 2012-06-12
HRP20060251B1 (hr) 2016-08-12
KR100804932B1 (ko) 2008-02-20
CA2396561A1 (en) 2001-07-05
EP1526132B1 (de) 2014-03-12
US7592339B2 (en) 2009-09-22
FR08C0051I1 (OSRAM) 2008-10-17
CA2396561C (en) 2008-10-14
HK1057556A1 (en) 2004-04-08
HUP0203902A2 (hu) 2003-03-28
UA73339C2 (en) 2005-07-15
MA25646A1 (fr) 2002-12-31
AR032436A1 (es) 2003-11-12
TR200401314T2 (tr) 2004-08-23
PL355665A1 (en) 2004-05-04
LTC1261606I2 (lt) 2021-05-10
US7585860B2 (en) 2009-09-08
CN1434822A (zh) 2003-08-06
JP5190173B2 (ja) 2013-04-24
US20030153610A1 (en) 2003-08-14
BG106825A (en) 2003-02-28
DK1261606T3 (da) 2005-05-09
TWI277615B (de) 2007-04-01

Similar Documents

Publication Publication Date Title
ATE289605T1 (de) Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung
EE200300485A (et) Tiohüdantoinid ja nende kasutamine diabeedi raviks
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60021576D1 (de) Absorbierendes wegwerfartikel mit haltezonen
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE69733558D1 (de) Saug- und spülhandstück und spitze
DE60043764D1 (de) Wegwerfwindel
DE60021475D1 (de) Wegwerfwindel
DE60018509D1 (de) Wegwerfwindel
DE59703261D1 (de) Substituierte Oxazolidinone und ihre Verwendung als antibakterielle Arzneimittel
DE60031513D1 (de) Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten
DE60030742D1 (de) Absorbierender wegwerfartikel
DE60312918D1 (de) Verbesserte bindefasern und vliesstoff mit bindefasern und absorbierendem material
DE60024528D1 (de) Wegwerfwindel
DE60209486D1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
DE60009635D1 (de) Vliesstoff mit Klebstoff und Öffnungen
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
DE10084522T1 (de) Hautfreundliche absorptionsfähige Artikel und Zusammensetzungen
DE60045459D1 (de) Wiederablösbarer Klebstoff und wiederablösbare Klebefolie
DE60025453D1 (de) Wegwerfwindel
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
ATE260627T1 (de) Verschluss und wegwerfartikel mit derartigem verschluss
DE60014751D1 (de) Wegwerfwindel